By Ariana Pelosci
A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.
Although hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin appeared to be well tolerated in patients … Read more
The combination of mirvetuximab soravtansine and bevacizumab produces “impressive antitumor activity” in patients with recurrent ovarian cancer and high folate receptor alpha (FRα) expression, according to researchers.… Read more
By Pam Harrison
Replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer, a phase III trial has shown.
In a cohort of nearly 700 women receiving carboplatin plus bevacizumab (Avastin), median … Read more
